These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19694740)

  • 1. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
    Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
    Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
    Keskitalo JE; Pasanen MK; Neuvonen PJ; Niemi M
    Pharmacogenomics; 2009 Oct; 10(10):1617-24. PubMed ID: 19842935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.
    Zhou Q; Ruan ZR; Yuan H; Zeng S
    Arzneimittelforschung; 2012 Nov; 62(11):519-24. PubMed ID: 22941809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.
    Keskitalo JE; Kurkinen KJ; Neuvoneni PJ; Niemi M
    Clin Pharmacol Ther; 2008 Oct; 84(4):457-61. PubMed ID: 19238649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.
    Tapaninen T; Neuvonen PJ; Niemi M
    Eur J Clin Pharmacol; 2010 Sep; 66(9):865-70. PubMed ID: 20496145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
    Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.
    Robertsen I; Asberg A; Granseth T; Vethe NT; Akhlaghi F; Ghareeb M; Molden E; Reier-Nilsen M; Holdaas H; Midtvedt K
    Transplantation; 2014 Jun; 97(12):1266-71. PubMed ID: 24521776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
    Aquilante CL; Wempe MF; Sidhom MS; Kosmiski LA; Predhomme JA
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1401-9. PubMed ID: 23407853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
    Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
    Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C > T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males.
    Lou XY; Zhang W; Wang G; Hu DL; Guo D; Tan ZR; Zhou HH; Chen Y; Bao HH
    Pharmazie; 2014 Oct; 69(10):775-9. PubMed ID: 25985569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
    Hoffman KB; Kraus C; Dimbil M; Golomb BA
    PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.
    Jensen BP; Roberts RL; Vyas R; Bonke G; Jardine DL; Begg EJ
    Br J Clin Pharmacol; 2012 Apr; 73(4):619-28. PubMed ID: 21999196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.